Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
Compass raises $132m in Series A as it moves from screening to the clinic, and start-up HotSpot Therapeutics comes out of stealth mode with a $45m Series A financing co-led by Atlas Venture and Sofinnova Partners.
Respiratory viral infections are a frequent cause of COPD exacerbations and the German major is joining forces with the Austrian biotech and Evotec to find new antivirals to tackle the disease.
Glenmark has drawn private equity interest for its carved out domestic orthopedic and pain management business as it seeks to fuel growth in these segments and pare debt via the proceeds. A similar strategy may be deployed for the firm's active pharmaceutical ingredients unit.
Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.
As others shun anti-infectives, Evotec is consolidating its position. Through an alliance with Sanofi it is evaluating new anti-infectives in three areas, and expects soon to advance its first candidate therapeutic into the clinic.
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.
Glenmark has sealed a licensing deal for its early stage immuno-oncology asset with China’s Harbour BioMed, opening up new possibilities around collaborations between the two Asian nations. The Indian firm appears upbeat about the prospects of building further on this new linkage.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.